Zolpidem: a review of its use in the management of insomnia.

doi:10.2165/00023210-200519010-00008

Paper

Zolpidem: a review of its use in the management of insomnia.

Published 2005 · Tracy Swainston Harrison, G. Keating

CNS drugs

288

Citations

7

Influential Citations

Full textSemantic Scholar

Abstract

Zolpidem (Ambien, Stilnox, Myslee, an imidazopyridine, is a nonbenzodiazepine hypnotic indicated for the short-term treatment of insomnia. Zolpidem improves sleep in patients with insomnia. Its overall tolerability is favourable when administered according to the manufacturer's prescribing information, with a low propensity to cause clinical residual effects, withdrawal, dependence or tolerance. In addition, most evidence suggests that the drug is associated with minimal rebound insomnia. In the only clinical trials that investigated the use of a hypnosedative drug in an 'as-needed' regimen, zolpidem produced a global improvement in sleep. Thus, zolpidem continues to be a useful therapeutic option in the pharmacological treatment of patients with insomnia.

Literature Review

Highly Cited

Study Snapshot

Zolpidem is a useful short-term treatment for insomnia with favorable tolerability and minimal rebound insomnia, making it a useful therapeutic option for insomnia management.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Zolpidem: a review of its use in the management of insomnia.

References

Citations